Evidence map›Paper›PMID 26912544›Full record

Observational studyClinical journal of the American Society of Nephrology : CJASN2016

Visit-to-Visit Variability of BP and CKD Outcomes: Results from the ALLHAT.

Jeff Whittle, Amy I Lynch, Rikki M Tanner, Lara M Simpson, Barry R Davis, Mahboob Rahman, Paul K Whelton, Suzanne Oparil, Paul Muntner

Abstract readObservational Study
In one paragraph

Observational study in Clinical journal of the American Society of Nephrology : CJASN, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Observational
  9. Article
  10. Article
  11. Article
  12. Observational
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Cumulative hypertension burden and risk of end-stage renal disease.Hypertension research : official journal of the Japanese Society of Hypertension · 2021
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Jeff WhittlePrimary Care Division, Clement J. Zablocki Veterans Affairs Medical Center, Milwaukee, Wisconsin; Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin; jeffrey.whittle@va.gov.
Amy I LynchDepartments of Epidemiology and.
Rikki M TannerDepartments of Epidemiology and.
Lara M SimpsonDivision of Biostatistics, University of Texas School of Public Health, Houston, Texas;
Barry R DavisDivision of Biostatistics, University of Texas School of Public Health, Houston, Texas;
Mahboob RahmanDepartment of Medicine, Case Western Reserve University, University Hospitals Case Medical Center, Cleveland, Ohio; Department of Medicine, Louis Stokes Cleveland Veterans Affairs Medical Center, Cleveland, Ohio; and.
Paul K WheltonDepartment of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana.
Suzanne OparilMedicine, University of Alabama, Birmingham, Alabama;
Paul MuntnerDepartments of Epidemiology and Medicine, University of Alabama, Birmingham, Alabama;

Funding

CLINICAL TRIALS CENTER FOR ALLHAT-N01HC35130-268035130N01HC035130 · HC · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · 1993 to 2005
$6.3M
Visit-to-visit variability of blood pressure and CVD and renal outcomesR01HL110993 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI MUNTNER, PAUL · 2012 to 2014
$1.1M
NHLBI NIH HHS HHSN268201100036CNHLBI NIH HHS N01 HC035130NHLBI NIH HHS N01-HC-35130NHLBI NIH HHS R01 HL110993
6 · The paper itself

Abstract

BACKGROUND AND

objectivesIncreased visit-to-visit variability of BP is associated with cardiovascular disease risk. We examined the association of visit-to-visit variability of BP with renal outcomes among 21,245 participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We measured mean BP and visit-to-visit variability of BP, defined as SD, across five to seven visits occurring 6-28 months after participants were randomized to chlorthalidone, amlodipine, or lisinopril. The composite outcome included incident ESRD after assessment of SD of systolic BP or ≥50% decline in eGFR between 24 months and 48 or 72 months after randomization. We repeated the analyses using average real variability and peak value of systolic BP and for visit-to-visit variability of diastolic BP.

resultsOver a mean follow-up of 3.5 years, 297 outcomes occurred. After multivariable adjustment, including baseline eGFR and mean systolic BP, the hazard ratios for the composite end point were 1.29 (95% confidence interval [95% CI], 0.75 to 2.22), 1.76 (95% CI, 1.06 to 2.91), 1.46 (95% CI, 0.88 to 2.45), and 2.05 (95% CI, 1.25 to 3.36) for the second through fifth (SD of systolic BP =6.63-8.82, 8.83-11.14, 11.15-14.56, and >14.56 mmHg, respectively) versus the first (SD of systolic BP <6.63 mmHg) quintile of SD of systolic BP, respectively (P trend =0.004). The association was similar when ESRD and a 50% decline in eGFR were analyzed separately, for other measures of visit-to-visit variability of systolic BP, and for visit-to-visit variability of diastolic BP.

conclusionsHigher visit-to-visit variability of BP is associated with higher risk of renal outcomes independent of mean BP.

Indexed as

Blood PressureGlomerular Filtration RateAgedAmlodipineAntihyperkalemic AgentsBlood Pressure DeterminationChlorthalidoneDisease ProgressionFemaleHumansHypertensionKidneyKidney Failure, ChronicLisinoprilMaleMiddle AgedAmlodipineAntihyperkalemic AgentsChlorthalidoneLisinoprilantihypertensive agentsblood pressureblood pressure variabilitycardiovascular diseasesclinical trialfollow-up studiesglomerular filtration ratehypertensionkidney failure, chronicrandom allocation

Identifiers

PMID26912544
PMCPMC4791814

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.